Skip to main content
OpenTrials
Completed

NCT Number: NCT05114005

Tango for Neuropathy Among Breast Cancer Survivors

Group dance classes have been found to improve markers of quality of life and physical health (i.e., balance) among some populations engaged in rehabilitation, such as the elderly and individuals with Parkinson Disease. However, such interventions have yet to be studied among cancer survivors despite the relevance of quality of life and physical health within cancer survivorship. Group dance classes are a promising avenue in that they deliver activity-based medicine in a social context, thus potentially improving physical as well as psychosocial aspects of health. To further this avenue of inquiry, we propose to study the effect of dance-based interventions for cancer survivors.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stephanie Spielman Comprehensive Breast Center

Columbus, Ohio, 43212, United States

About this study

Participants will be randomized (1:1) to one of two activity intervention arms: Argentine Tango dance or home exercise. Information about neuropathy symptoms, motion, falls incidence, and participant feedback about the interventions will be collected.

Aim1: To evaluate change in postural control over 16 sessions of Tango (exp) vs HEX (control) (n=26 per group) as primary endpoint. As secondary measures, to assess: balance function (i.e., TUG) and patient-reported outcomes (PROs) (i.e., symptoms, pain, fatigue, mood, quality of life) monthly including 1 month post-intervention completion; postural control and symptoms within-session; and falls incidence weekly for 6 months following intervention completion. Hypothesis: At primary endpoint, participants in the experimental group will show more improvement than participants in the control group in measures sensitive to neuropathy disease state (i.e., sway variability and area).

Aim2: To evaluate change in gait variability after 16 sessions of Tango (exp) vs HEX (control) (n=26 per group; 1:1 randomization). As secondary measures, to analyze local and orbital dynamic stability (pre, post, and 1mo post-intervention), PROs (monthly), and falls incidence (weekly) following intervention completion. Hypothesis: At primary endpoint, participants in the experimental group will show more improvement than participants in the control group in measures of gait variability (i.e., stride-to-stride variability in speed).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Breast cancer survivor stage I-III
  • Symptomatic for neuropathy
  • postural control outside 70% CI for adults who are middle-aged without neurotrauma
  • having completed taxane-based chemotherapy treatment at least 3 months ago;
  • able to understand and comply with directions associated with testing and study treatments.

Exclusion criteria

  • Pre-existing vestibular deficit;
  • poorly controlled diabetes (hgA1C > 8);
  • non-ambulatory or lower extremity amputation (assistive devices allowed);
  • use of cytotoxic or immunotherapy during study (endocrine therapy allowed);
  • participation in physical therapy during the study;
  • contraindication to participate in Tango due to orthopedic issue (e.g., herniated vertebral disc);

Treatment and study plan

Rhythmic Auditory Stimulation

Behavioral

Rhythmically-entrained sensorimotor activity.

Evidence-Based Exercise

Behavioral

This program consists of information on neuropathy and fall prevention combined with a schedule of 1 hour training (i.e., endurance, resistance, and sensorimotor) performed 2x per week

Primary outcomes

  1. Postural Control (Variability)

    Time frame: At baseline, week 8 of intervention, and at 4 week follow-up post intervention

    root-mean square of the center of pressure (COP)

  2. Intrinsic Motivation

    Time frame: Assessed at week 4, week 8, and week 12

    Intrinsic motivation will be measured using a subscale of the Intrinsic Motivation Inventory (IMI). The 6 item Interest/Enjoyment subscale of the IMI represents intrinsic motivation in an activity just performed as a possible score of 6 to 36 with 6 = most; 18 = neutral; 36 = least interesting/enjoyable. Specific items queried include whether the activity just performed was: enjoyable, enjoyed, boring (reverse order), interesting, fun, and able to hold the participant's attention.

Secondary outcomes

  1. Postural Control (Ellipse Area)

    Time frame: At baseline, week 8 of intervention, and at 4 week follow-up post intervention

    95% ellipse area of the COP

  2. Postural Control (Velocity)

    Time frame: At baseline, week 8 of intervention, and at 4 week follow-up post intervention

    velocity of COP

  3. Postural Control (Complexity)

    Time frame: At baseline, week 8 of intervention, and at 4 week follow-up post intervention

    sample entropy of the center of pressure (COP). Sample entropy is a non-linear COP measure that determines the irregularity of a time-series. Sample entropy of the resultant COP position will be calculated using the increment calculation method (SEI) with constant values applied of m = 3 and r = 0.3. Entropy of postural responses represents the automatic complexity of neuromotor control that is available to an individual. Sample entropy scores won't go below 0 or above 2, and higher values indicate better complexity in postural response

  4. Postural Control (Variability) at Tango Sessions

    Time frame: at the beginning and at the end of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    root-mean square of the center of pressure (COP). The mean will be taken of all beginning of session data points together and all end of session data points together. Lower numbers indicate better neuromotor health.

  5. Postural Control (Ellipse Area) at Tango Sessions

    Time frame: at the beginning and at the end of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    95% ellipse area of the COP. The mean will be taken of all beginning of session data points together and all end of session data points together. Lower numbers indicate better neuromotor health.

  6. Postural Control (Velocity) at Tango Sessions

    Time frame: at the beginning and the end of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    velocity of COP. The mean will be taken of all beginning of session data points together and all end of session data points together. Lower numbers indicate better neuromotor health.

  7. Postural Control (Complexity) at Tango Sessions

    Time frame: at the beginning and the end of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    sample entropy of the center of pressure (COP). Sample entropy is a non-linear COP measure that determines the irregularity of a time-series. Sample entropy of the resultant COP position will be calculated using the increment calculation method (SEI) with constant values applied of m = 3 and r = 0.3. Entropy of postural responses represents the automatic complexity of neuromotor control that is available to an individual. Sample entropy scores won't go below 0 or above 2, and higher values indicate better complexity in postural responseThe mean will be taken of all beginning of session data points together and all end of session data points together

  8. Clinical Measure of Balance Function

    Time frame: At baseline, week 4 of intervention, and at 4 week follow-up post intervention, up to 12 weeks

    The Timed Up-and-Go test, or TUG, (<2 min to administer) is a timed test of a person's ability to stand from a chair, walk 10 feet, turn around, and return to sitting with shorter times indicating better functional balance.

  9. Neuropathy Symptoms Score at Tango Sessions

    Time frame: at the beginning and the end of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire, Chemotherapy-Induced Peripheral Neuropathy (CIPN 20): is a validated instrument for longitudinal evaluation of neuropathy symptoms induced by chemotherapy. This is a 20-item patient reported questionnaire. It is easy to use and filled out by patients themselves. Scores range between 1 to 10 with higher scores indicating greater chemotherapy-induced peripheral neuropathy (CIPN) severity. The mean will be taken of all beginning of session data points together and all end of session data points together

  10. Neuropathy Symptoms Score

    Time frame: At week 8 of intervention and at 4-week follow-up post intervention

    European Organization for Research and Treatment of Cancer's Quality of Life Questionnaire, Chemotherapy-Induced Peripheral Neuropathy (CIPN 20): is a validated instrument for longitudinal evaluation of neuropathy symptoms induced by chemotherapy. This is a 20-item patient reported questionnaire. It is easy to use and filled out by patients themselves. Scores range between 1 to 10 with higher scores indicating greater chemotherapy-induced peripheral neuropathy (CIPN) severity.

  11. Brief Pain Inventory Short Form at Tango Sessions

    Time frame: at the beginning and the end of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    The Brief Pain Inventory Short Form (BPI) is a validated instrument used to evaluate pain symptoms and functional capacity "right now" using a single item visual analog scale (VAS) on which participants will rate how much pain they are in "right now" on a scale of 1 to 10 (10 being high the worst pain imaginable). The mean will be taken of all beginning of session data points together and all end of session data points together

  12. Brief Pain Inventory Short Form

    Time frame: At week 8 of intervention and at 4-week follow-up post intervention

    The Brief Pain Inventory Short Form (BPI) is a validated instrument used to evaluate pain symptoms and functional capacity "right now" using a single item visual analog scale (VAS) on which participants will rate how much pain they are in "right now" on a scale of 1 to 10 (10 being high the worst pain imaginable).

  13. Cancer-Related Fatigue (BFI Scores) at Tango Sessions

    Time frame: at the beginning and the end of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    The Brief Fatigue Inventory (BFI) is used to rapidly assess the severity and impact of cancer-related fatigue "right now" using a single item visual analog scale (VAS) on which participants will rate how much fatigue they feel "right now" on a scale of 1 to 10 (10 being high the worst fatigue imaginable). The mean will be taken of all beginning of session data points together and all end of session data points together

  14. Cancer-Related Fatigue

    Time frame: At week 8 and at 4-week follow-up visit post intervention

    The Brief Fatigue Inventory (BFI) is used to rapidly assess the severity and impact of cancer-related fatigue "right now" using a single item visual analog scale (VAS) on which participants will rate how much fatigue they feel "right now" on a scale of 1 to 10 (10 being high the worst fatigue imaginable).

  15. Number of Falls

    Time frame: once at the point of study enrollment

    the number of falls or near falls that the participant remembers experiencing in the month prior to enrollment in the study will be assessed. All reported falls will be totaled and reported by arm.

  16. Number of Falls

    Time frame: at the beginning of each assessment or intervention session for up to 20 sessions, up to 8 weeks

    the number of falls or near falls experienced by the participant since last evaluation/intervention session. All reported falls throughout the intervention time period will be totaled and reported by arm.

  17. Number of Falls

    Time frame: 6 months post-intervention

    the number of falls or near falls experienced by the participant in the 6 months post-intervention. All reported falls throughout the follow-up time period will be totaled and reported by arm

  18. Change in Dual-task Function

    Time frame: Assessed at baseline, 4 weeks, 8 weeks, and 12 weeks

    Dual task function was measured using the Timed-Up-and-Go motor task while counting backward by 3 s (TUGCog), a validated clinical test of dual-task function for which lower values indicate better performance. To perform this test, participants completed the Timed-Up-and Go (TUG) test commonly used in clinical practice wherein individuals stand from a chair with arms, walk 3 meters, turn around, and return to sitting as fast as safely possible (i.e. motor task) while counting out loud and backward by 3 s (i.e. cognitive task). The test is completed 3 times, with rest allowed between trials. Time in seconds per trial is averaged to produce the TUGCog score per timepoint.

  19. Adherence

    Time frame: Assessed at baseline, 4 weeks, 8 weeks, and 12 weeks

    Adherence is measured by the number of enrollees who participated through each time point of the study

Other outcomes

  1. Quantified Clinical Measure of Balance Function

    Time frame: 8 weeks

    The Mini Balance Evaluation System Test short version (MiniBEST): evaluates sensory organization, anticipatory and reactive postural control, and dynamic gait indices on a scale from 1 to 28 points (28 represents the highest function measurable by the test); was recently recommended for use in studies of neuropathy; and discriminated BC survivors from controls in at least 1 prior study. Instrumentation of MiniBEST will enable the calculation of spatiotemporal, kinematic, and co-contraction measures

  2. Quantified Clinical Measure of Balance Function

    Time frame: 1 month follow-up post-intervention

    The Mini Balance Evaluation System Test short version (MiniBEST): evaluates sensory organization, anticipatory and reactive postural control, and dynamic gait indices on a scale from 1 to 28 points (28 represents the highest function measurable by the test); was recently recommended for use in studies of neuropathy; and discriminated BC survivors from controls in at least 1 prior study. Instrumentation of MiniBEST will enable the calculation of spatiotemporal, kinematic, and co-contraction measures.

Sponsors and collaborators

Lead sponsor

Ohio State University Comprehensive Cancer Center

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Official study title

Dance-Based Avenues to Advance Nonpharmacologic Treatment of Chemotherapy Effects (DAANCE)

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Nov 9, 2021
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.